Show simple item record

dc.contributor.authorŞeker, Mesut
dc.contributor.authorİsen, Hayati Can
dc.contributor.authorÇevirme, Nidal
dc.contributor.authorAydın, Sinem
dc.contributor.authorBilici, Ahmet
dc.contributor.authorBulut, Huri
dc.contributor.authorYasin, Ayşe İrem
dc.contributor.authorÇoban, Ezgi
dc.contributor.authorDemir, Tarık
dc.contributor.authorAliyev, Altay
dc.contributor.authorKoçyiğit, Abdurrahim
dc.contributor.authorTürk, Hacı Mehmet
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:02:14Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:02:14Z
dc.date.issued2018en_US
dc.identifier.citationŞeker, M., İsen, H. C., Çevirme, N., Aydın, S., Bilici, A., Bulut, H. ... Türk, H. M. (2018). Role of urotensin-2 in 5-fluorouracil-related arterial vasoconstriction in cancer patients. Journal of Oncology Research and Treatment, 41(9), 545-549. https://dx.doi.org/10.1159/000490120en_US
dc.identifier.issn2296-5270
dc.identifier.issn2296-5262
dc.identifier.urihttps://dx.doi.org/10.1159/000490120
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3589
dc.descriptionWOS: 000444108500007en_US
dc.descriptionPubMed ID: 30121640en_US
dc.description.abstractBackground: The aim of this study was to identify the possible relationship of 5-fluorouracil (5-FU)-related arterial vasoconstriction with urotensin-2 (UT-2), which has a high potential as an endogenic vasoconstrictor. Methods: We assigned the patients to 1 of 3 groups. Patients in group 1 received a bolus of 5-FU, those in group2a continuous infusion (CI) of 5-FU, and those in group 3 no 5-FU, which was also a control group. Pre- and post-treatment UT-2 levels and brachial arterial diameters were measured and recorded in all patients. Results: 132 patients were included in the study. Pre-and post-treatment brachial artery diameters were similar in all groups: in group 1 (3.28 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.740), in group 2 (3.57 +/- 0.47 vs. 3.46 +/- 0.45 mm, p = 0.441) and in the control group (3.51 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.818). Pre-and post-treatment UT-2 levels were significantly different in each group: in group 1 (39.5 +/- 30.9 vs. 56.7 +/- 27.1 ng/ml, p = 0.0001), in group 2 (37.7 +/- 33.7 vs. 62.5 +/- 37.7 ng/ml, p = 0.0001) and in the control group (52.9 +/- 40.2 vs. 60.8 +/- 40.7 ng/ml, p = 0.006). Conclusion: Our findings suggest that UT-2 has a high potential as a vasoconstrictor agent in our bodies and its level increases through a bolus or CI 5-FU. Increased UT-2 levels are likely to play a role in 5-FU-related cardiac toxicity pathogenesis.en_US
dc.language.isoengen_US
dc.publisherKargeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject5-Fluorouracilen_US
dc.subjectCardiotoxicityen_US
dc.subjectUrotensin 2en_US
dc.subjectVasoconstrictionen_US
dc.titleRole of urotensin-2 in 5-fluorouracil-related arterial vasoconstriction in cancer patientsen_US
dc.typearticleen_US
dc.relation.journalOncology Research and Treatmenten_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume41en_US
dc.identifier.issue9en_US
dc.identifier.startpage545en_US
dc.identifier.endpage549en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1159/000490120en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record